iRhythm Technologies (IRTC) investor relations material

Market Trends and Opportunities

• Aging population and increased arrhythmia prevalence are driving demand for cardiac monitoring solutions, with significant gaps in access to cardiologists, especially in rural areas.

• Significant unmet need exists, with 27 million undiagnosed arrhythmia cases in the U.S. alone.

• Trends such as increased arrhythmia awareness, new therapies, and value-based care are expanding the total addressable market.

• Expansion into primary care and international markets is a key growth strategy, with less than 1% share internationally and ongoing efforts in the UK, EU, and Japan.

• AI-driven predictive monitoring and integration with comorbid disease management are opening new market segments.

Product and Technology Innovation

• Second-generation FDA-approved AI algorithm is in use, with a third-generation algorithm and next-generation MCT device under FDA review, offering improved form factor and detection.

• New MCT product with 21-day monitoring is expected to launch in early 2027, addressing physician demand for longer duration.

• Platform features patented wearable biosensors, advanced AI-driven ECG detection, and seamless EHR integration.

• Integration of additional sensing capabilities (PPG, SpO2, hypertension, respiratory rate) is underway.

• ZioSuite digital ecosystem streamlines prescribing, monitoring, and diagnosis for providers.

Financial Performance and Guidance

• 2025 revenue expected to exceed $740 million, with first-time profitability and free cash flow positivity.

• 2026 revenue guidance is $870–$880 million, representing 17–18% growth and margin expansion to 11.5–12.5%.

• Adjusted EBITDA margin targeted at 11.5–12.5% for 2026, with a path to 15% as revenue approaches $1 billion.

• Gross margin expansion and G&A leverage are key drivers of profitability improvement.

• Investment in growth opportunities is balanced with disciplined cost management and operational automation.